by | Mar 9, 2022 | Alhallak, Kinan, Azab, Abdel Kareem
— Disease indication – multiple myeloma
Drug format – antibodies conjugated to nanoparticles for T-cell immunotherapy
Drug class – improved delivery platform
Research stage and Preliminary data:
In vivo:
In vitro proof of concept – in a MM cell line: NanoMuTEs and NanoTC…
by | Mar 2, 2022 | Lim, Kian-Huat, Liu, Yongjian, Zhang, Xiaohui
— Disease indication –
Drug format – Combination containing radiolabeled copper nanocluster, small molecule, and peptide
Drug class – First-in-class
Target – CCR2, the receptor for CCL2
Mode of action – The ECL1i peptide is conjugated to a copper nanocluster loaded…
by | Feb 21, 2022 | Curcuru, Austen, Gach, H. Michael, Kim, Taeho, Villa, Umberto
— Technology Description
Researchers at Washington University in St. Louis have developed a method to improve image quality during MR imaging guided radiation therapy (MR-IGRT) by correcting for B0 fluctuation in real-time. The corrections reduce electromagnetic interference (EMI) between the MRI sc…
by | Feb 16, 2022 | Azab, Abdel Kareem, Federico, Cinzia
— Technology Description
Researchers in Prof. Kareem Azab’s laboratory have developed a liposome drug delivery vehicle to improve efficacy and reduce side effects of multiple myeloma treatment. This system is designed to target compounds to the bone marrow microenvironment (BMME) and simultane…
by | Feb 16, 2022 | Azab, Abdel Kareem, Muz, Barbara
— Researchers in Prof. Abdel Kareem Azab’s laboratory have developed a biologically-targeted cellular drug delivery system to precisely target therapeutic or diagnostic agents to a wide range of cancers. Delivering drugs directly to cancer cells and not to healthy cells could improve outcomes by…